AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01164189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
Study NCT00217412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study NCT02144584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine XR
Description: The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
Study NCT02144584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for memantine)
Description: Placebo to be capsuled to look identical to active drug (memantine)
Study NCT01172353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
Study NCT01172353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: hydration with saline 1ml/Kg/h for 6 hours
Study NCT01856985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT01856985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT01841606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4mg of IV ondansetron
Study NCT01841606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10mL of IV normal saline
Study NCT00686920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Oral
Study NCT00783679 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NICO device
Description: Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy.
Study NCT02345278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC FIX Mite mixture
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
Study NCT02345278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
Study NCT04495777 — intervention group
Intervention type: OTHER
Intervention: Fonseca Anamnestic Index
Description: Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT02763579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
Study NCT04202900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: phototherapy protocol
Description: Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.
Study NCT01206361 — intervention group
Intervention type: DRUG
Intervention: XALACOM
Description: Xalacom eye drops
Study NCT01206361 — intervention group
Intervention type: DRUG
Intervention: Duotrav
Description: Duotrav eye drops
Study NCT01206361 — intervention group
Intervention type: DRUG
Intervention: Ganfort
Description: Ganfort eye drops
Study NCT03502629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study NCT00939133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin microsphere 0.04% gel
Description: Applied daily to entire face for six months
Study NCT00939133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Placebo
Study NCT01523795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-controlled video gaming
Description: Play of motion-controlled video games for one hour
Study NCT01523795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional video gaming
Description: Participants played traditional video games for one hour
Study NCT01523795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Television watching
Description: Participants watched television for one hour
Study NCT02970669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan (LCZ696)
Description: sacubitril/valsartan tablet taken orally.
Study NCT02970669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696)
Description: sacubitril/valsartan tablet taken orally.
Study NCT02970669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enalapril
Description: Enalapril tablet taken orally.
Study NCT02970669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo sacubitril/valsartan (LCZ696)
Description: matching placebo sacubitril/valsartan tablet taken orally
Study NCT02970669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo enalapril
Description: matching placebo enalapril tablet taken orally
Study NCT03929224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal honey
Description: Treat healing surgical site with medicinal honey
Study NCT03929224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Treat healing surgical site with bacitracin
Study NCT03171298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Transanal Total Mesorectal Excision
Description: * Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally
Study NCT06670703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Obesity
Description: diagnosis as obese patients
Study NCT03760237 — intervention group
Intervention type: OTHER
Intervention: observation only
Description: No intervention, observational study only
Study NCT06669936 — intervention group
Intervention type: DRUG
Intervention: Fecal microbiota transplantation ± bezlotoxumab
Description: Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
Study NCT01818323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-tumoral T4 immunotherapy
Description: Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
Study NCT03567915 — intervention group
Intervention type: OTHER
Intervention: Evaluation of gastric volume and content
Description: The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
Study NCT03164590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
Study NCT03164590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
Study NCT03164590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
Study NCT03164590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
Study NCT03164590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high sodium diet
Description: high sodium diet
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low sodium diet
Description: low sodium diet
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril 10 mg
Description: ramipril 10 mg
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Description: valsartan 160 mg
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan 8 mg
Description: candesartan 8 mg
Study NCT00310778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Description: atenolol 50 mg
Study NCT03641118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
Study NCT01289509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Lot P01010ZZA (test) single oral doses of 40 mg tablets.
Study NCT01289509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: E5501
Description: Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
Study NCT03772639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making
Description: Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
Study NCT03141177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT06775652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Patients assigned to the NCRT group received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles. Concurrently, they received intensity-modulated radiotherapy (IMRT) with a total of 20 sessions (CTV 40 Gy, GTV 44 Gy) five days per week. All radiotherapy plans were reviewed by designated radiation oncologists before treatment to ensure quality control. Patients were assessed 4 to 6 weeks after completing NCRT following RECIST 1.1 criteria.
Study NCT06775652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Patients in the AT group received surgery as soon as possible after randomization, followed by adjuvant therapy, postoperative adjuvant therapy based on pathological staging, as recommended by the NCCN Clinical Practice Guidelines for Esophageal and Esophagogastric Junction Cancers (2017 V4), starting one month post-surgery with either adjuvant chemotherapy or chemoradiotherapy. The adjuvant chemotherapy regimen was the same as the neoadjuvant chemotherapy regimen, and the adjuvant radiotherapy regimen and dose were administered according to guideline recommendations.
Study NCT03141177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days
Study NCT06775652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study NCT06775652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT03141177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Specified dose on specified days.
Study NCT03141177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04728113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care visit with questionnaires
Description: 5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
Study NCT04728113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oncological standard visit
Description: Oncological standard visit
Study NCT04728113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological standard visit
Description: Oncological standard visit
Study NCT03279484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV lead implant
Description: All patients will be attempted to implant or implanted with NAVIGO 4LV lead
Study NCT00947011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 100 mg once a day
Study NCT00947011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia
Description: 1 tablet 100 mg once a day
Study NCT04527887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
Description: Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
Study NCT04527887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProLong™ collagen plugs
Description: The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
Study NCT02201927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanic vestibular stimulation
Study NCT04525391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab+AZD2811 to SCLC patients
Description: AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
Study NCT03297788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)
Study NCT03297788 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
Study NCT01907087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 190
Description: 30-300 mg ICV infusion administered every other week for at least 48 weeks.
Study NCT02984839 — intervention group
Intervention type: DEVICE
Intervention: Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology
Description: Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
Study NCT02850523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Perinatal Anxiety
Description: The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
Study NCT03642574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CNV
Description: Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
Study NCT04793503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional complete denture
Description: the complete denture constructed by packing technique
Study NCT04793503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CADCAM 3D printed denture
Description: The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
Study NCT04793503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM milled denture
Description: Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
Study NCT03000400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Traumatic Brain Injury Family System Intervention.
Description: Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
Study NCT03000400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational session at OUH
Description: 2.5 hour psycho-educational session for the patient's family members.
Study NCT03246698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching group
Description: In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
Study NCT03246698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching group
Description: In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
Study NCT02203461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
Description: STRIBILD® QD, d1-14
Study NCT02203461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
Description: Truvada®/ Kaletra® 200/50 mg QD, d1-14
Study NCT02203461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
Description: Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14